Aspects of 3-iodothyronamine (3T1AM) induced signaling by human and mouse trace amine-associated receptor 5 (TAAR5)

Mühlhaus, Jessica; Dinter, Juliane; Piechowski, CL; Müller, André; Nürnberg, Daniela; Grüters, Annette; Köhrle, Josef; Yi, CX; Tschöp, MH; Krude, Heiko; Kleinau, Gunnar; Biebermann, Heike

doi:10.1055/s-0034-1372013

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these models T1AM was more potent than all other trace amines. Preliminary evidence that T1AM interacts with TAAR5 has been reported (Mühlhaus et al, 2013 ), and TAAR8 has also been suggested as a potential target, on the basis of the pharmacological effects produced in the isolated rat heart (Frascarelli et al, 2008 ).…”

Section: T1am Receptors and Binding Sitesmentioning

confidence: 99%

Update on 3-iodothyronamine and its neurological and metabolic actions

2014

View full text Add to dashboard Cite

3-iodothyronamine (T1AM) is an endogenous amine, that has been detected in many rodent tissues, and in human blood. It has been hypothesized to derive from thyroid hormone metabolism, but this hypothesis still requires validation. T1AM is not a ligand for nuclear thyroid hormone receptors, but stimulates with nanomolar affinity trace amine-associated receptor 1 (TAAR1), a G protein-coupled membrane receptor. With a lower affinity it interacts with alpha2A adrenergic receptors. Additional targets are represented by apolipoprotein B100, mitochondrial ATP synthase, and membrane monoamine transporters, but the functional relevance of these interactions is still uncertain. Among the effects reported after administration of exogenous T1AM to experimental animals, metabolic and neurological responses deserve special attention, because they were obtained at low dosages, which increased endogenous tissue concentration by about one order of magnitude. Systemic T1AM administration favored fatty acid over glucose catabolism, increased ketogenesis and increased blood glucose. Similar responses were elicited by intracerebral infusion, which inhibited insulin secretion and stimulated glucagon secretion. However, T1AM administration increased ketogenesis and gluconeogenesis also in hepatic cell lines and in perfused liver preparations, providing evidence for a peripheral action, as well. In the central nervous system, T1AM behaved as a neuromodulator, affecting adrenergic and/or histaminergic neurons. Intracerebral T1AM administration favored learning and memory, modulated sleep and feeding, and decreased the pain threshold. In conclusion T1AM should be considered as a component of thyroid hormone signaling and might play a significant physiological and/or pathophysiological role. T1AM analogs have already been synthetized and their therapeutical potential is currently under investigation. 3-iodothyronamine (T1AM) is a biogenic amine whose structure is closely related to that of thyroid hormone (3,5,3′-triiodothyronine, or T3). The differences with T3 are the absence of the carboxylate group and the substitution of iodine with hydrogen in 5 and 3′ positions (Figure 1). In this paper we will review the evidence supporting the hypothesis that T1AM is a chemical messenger, namely that it is an endogenous substance able to interact with specific receptors producing significant functional effects. Special emphasis will be placed on neurological and metabolic effects, which are likely to have physiological and pathophysiological importance.

show abstract

Section: T1am Receptors and Binding Sitesmentioning

confidence: 99%